Product Description
For Major Depressive Disorder
Mechanisms of Action: 5-HT Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Sunshine Lake Pharma
Company Location: Asia Pacific
Company Founding Year: 2011
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Depressive Disorder, Major
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04984512 |
HEC113995-P-5 | P3 |
Recruiting |
Depressive Disorder, Major |
2027-07-01 |
15% |
2026-05-06 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|